Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Carbamazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 1.00 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | P2RX4 | Q99571 | 16/20 | 0.74 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.56 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamazepine SCHEMBL29360181 | 1.00 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29433237 | 1.00 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL21639 | 1.00 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL31685158 | 1.00 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL1421962 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29390487 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL28169915 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29023618 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL5382102 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL27589204 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117956991-A | N, N-dimethyltryptamine and related hallucinogens and uses thereof | 人类生物科学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20170362182-A1 | MULTIPLE-COMPONENT SOLID PHASES CONTAINING AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT | UNIVERSITY OF SOUTH FLORIDA | 2017-12-21 | — | — | US | disclosed |
| EP-3137065-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | Pharnext (FR) | 2017-03-08 | — | — | EP | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2892518-A2 | NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | Pharnext (FR) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037416-A2 | NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | PHARNEXT (FR) | 2014-03-13 | — | — | WO | disclosed |
| WO-2013037003-A1 | IMPROVEMENTS RELATING TO DECISION SUPPORT | GENESFX HEALTH PTY LTD (AU) | 2013-03-21 | — | — | WO | disclosed |
| CN-101528196-A | Self-emulsifying compositions for poorly bioavailable drugs | HOVID BERHAD (MY) | 2009-09-09 | — | — | CN | disclosed |
| WO-2005112911-A2 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-1061802-B1 | TOPICAL CARBAMAZEPINE FORMULATIONS AND METHODS OF USE | TARO PHARMACEUTICALS USA INC (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20020198192-A1 | Topical carbamazepine formulations | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-12-26 | — | — | US | disclosed |
| US-6486152-B1 | Topical carbamazepine formulations and methods of use | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-11-26 | — | — | US | disclosed |
| US-RE34990-E | Anticonvulsants, treatment of epilepsy, carbamazepine | CIBA-GEIGY CORPORATION (US) | 1995-07-04 | — | — | US | disclosed |
| US-5122543-A | Syrup of carbamazepine in protective polymeric colloid | CIBA-GEIGY CORPORATION (US) | 1992-06-16 | — | — | US | disclosed |
| US-4857336-A | Oral therapeutic system having systemic action | CIBA-GEIGY CORPORATION (US) | 1989-08-15 | — | — | US | disclosed |